President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

President Trump will continue to pursue the policy of Medicare pricing negotiation introduced by former President Biden's Inflation Reduction Act (IRA) but will look at refining the programme.

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

The U.S. Centers for Medicare & Medicaid Services, or CMS, said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated under the Inflation ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...

A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

RFK Jr.'s confirmation hearings continue today as he appears before a second Senate committee. Follow STAT's live updates.

Robert F. Kennedy Jr. told the Senate Finance Committee that he is not anti-vaccine during his confirmation hearing for ...

Weight loss drugs are popular—but often expensive. Luckily, there are a few ways to lower the costs, which we explore in this article.

In a healthcare market brimming with potential, DarioHealth Corp. * is quietly emerging as a standout player, combining cutting-edge technology with proven outcomes. Looking at recent achievements, it ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...